Press

Highlights

The secretome as 21st century medicine

FIRST CONFERENCE AUTONOMOUS UNIVERSITY OF MADRID AND PEACHES DEMONSTRATES THE SUCCESSFUL UNION OF OUR RESEARCH FORCES, THE ACADEMIC, UNIVERSIDAD AUTÓNOMA DE MADRID, AND THE INDUSTRY, PEACHES BIOTECH - The UAM-PEACHES Chair in Cellular Therapies at the Autonomous...
Read More

Peaches Biotech receives 598,000 euros from the CDTI for its PRS project on advanced therapies

The Center for Technological Development and Innovation (CDTI), of the Ministry of Science and Innovation, has approved a project of the Spanish company Peaches Biotech, considering it highly innovative, providing it with 598,000 euros. The selected research...
Read More

Peaches Biotech, the Universidad Autónoma of Madrid (UAM) and its Foundation create the first University Chair in Advanced Therapies

We have created with the Universidad Autónoma of Madrid (UAM) and its Foundation (FUSM) the first University Chair in Advanced Therapies based on cell secretomes The UAM-Peaches Chair will promote research and teaching in the areas of Cellular Therapy and Regenerative...
Read More

Peaches obtains financial approval from the Ministry of Science and Innovation for two of its advanced therapy projects

PRESS RELEASE Peaches has the demanding scientific and technological recognition of AEI The State Research Agency (AEI) of the Ministry of Science and Innovation approves funding for two Peaches Biotech projects in its call for public-private collaboration. The...
Read More

International Cancer Research Day

We share with you this interesting interview in Con Salud, one of the leading media in the health sector, about our novel and promising approach to pancreatic cancer treatment. Juan Carlos de Gregorio, our CEO and founder, explains in plain language the advances...
Read More

A new approach for the treatment of infection-associated cytokine storm.

Did you know that cytokine storm, associated with severe infectious processes, is a serious global health problem for which there is no effective drug for treatment? Peaches Biotech's Chief Scientific Officer publishes results of his research against the cytokine...
Read More

“We are closer and a cure for pancreatic cancer will be feasible.”

Interview with Manuel Hidalgo, research associate at Peaches Biotech, in the supplement A tu Salud of La razón. Research talent is one of our company's greatest assets. On this occasion, Manuel Hidalgo, Director of the Division of Hematology-Oncology at Weill Cornell...
Read More

Peaches Biotech is working on a new approach against pancreatic cancer.

Tribune published in El Economista   Our CEO, Juan Carlos de Gregoriohas had the opportunity to publish in The Economist a forum where he shares his vision on the current treatments for pancreatic cancer, as well as the new approach proposed by Peaches against...
Read More

New biotechnology platform enables production of complex biologic drugs for allogeneic use

Combined in silico and experimental research to test the potential immunogenicity of a new complex biologic drug (PRS CK STORM).   The American Journal of Biomedical Science and Research has published and endorsed a new article on our drug PRS CK STORM. You can...
Read More

Peaches Biotech publishes positive in vivo results of its drug PRS CK STORM

Peaches Biotech publishes positive in vivo results of its drug PRS CK STORM against cytokine storm associated with infectious processes

Read More

Granulisina, the hopeful “projectile” against cancer created by Spanish scientists

Published por ABC The research, led by the University of Zaragoza, advances in the clinical use of a human antitumor protein combined with antibodies. Its efficacy has already been proven in mice, in colon and gastric tumors. A human protein, granulysin, combined with...
Read More

Reinterpreting polarity and cancer: The changing landscape from tumor suppression to tumor promotion.

Published by PubMed 2018 Apr;1869(2):103-116. doi: 10.1016/j.bbcan.2017.12.001. Epub 2018 Jan 31. Reinterpreting polarity and cancer: The changing landscape from tumor suppression to tumor promotion. Yasuhiro Saito , Ridhdhi R Desai , Senthil K Muthuswamy Affiliations...
Read More

PDX-derived organoids model in vivo drug response and secrete biomarkers

Publicado por PubMed 2020 Nov 5;5(21):e135544. doi: 10.1172/jci.insight.135544. PDX-derived organoids model in vivo drug response and secrete biomarkers Ling Huang 1 2, Bruno Bockorny 1 2, Indranil Paul 3, Dipikaa Akshinthala 1 2, Pierre-Oliver Frappart 4, Omar...
Read More

Peaches Biotech to develop Harvard patent to identify pancreatic tumor cells

Published in infosalus.com The Madrid-based company Peaches Biotech announced on Thursday the incorporation into its research project of a worldwide patent from Harvard University that makes it possible to identify and attack pancreatic tumor cells and other solid...
Read More

The Madrid SME Peaches Biotech buys the patent against pancreatic cancer from Harvard

Published by: El Economista The drain of brains and ideas is the norm of Spanish science. But there are always exceptions and one of them is represented by Peaches Biotech. This Madrid SME crossed the Atlantic to land at the prestigious Harvard University and bought a...
Read More

Interview with Peaches Biotech’s CEO on Negocios TV

https://www.youtube.com/watch?v=MOoUGvjvkIE  
Read More

“Our approach is very mindful of the specificity of each tumor in each patient.”

The online healthcare newspaper Con Salud has interviewed our research associate, Dr. Senthil Muthuswamy, Director of Translational Research at the Beth Israel Deaconess Hospital Cancer Center in Boston, and published in detail what the platform consists of. opT of...
Read More

Peaches Biotech deciphers communication language between immune cells and other tissues

Peaches Biotech publishes in Biomolecules its work on how the immune system communicates with tissues damaged or attacked by viruses or bacteria. This breakthrough opens a way to find new drugs, of biological origin, of great importance in advanced therapies such as...
Read More

Intercellular communication (crosstalk) to fight inflammation and fibrosis

Design of new biological drugs At Peaches Biotech we continue to advance in the dissemination of the concept and the possibilities that open up with intercellular communication (crosstalk) and its therapeutic possibilities. The publication in the American Journal of...
Read More

Peaches Biotech publishes positive in vivo results of its drug PRS CK STORM

Peaches Biotech publishes positive in vivo results of its drug PRS CK STORM against cytokine storm associated with infectious processes

Read More

News

Here you will find the latest publications related to the companies that are part of the Peaches Biotech group.
Each article contains the link to the page where the news is published.

Europe Next 2050

Europe Next 2050

Mar 25, 2022

On February 24, we participated in the meeting Europe Next 2050 inaugurated by the Secretary of State for Trade, Xiana Mèndez, where we contributed with our vision of biotechnology at the discussion table on the Industry 4.0 . Our CEO and founder, Juan Carlos...

GENERAL CONTACT

info@peaches.es

MEDIA CONTACT

comunicacion@peaches.es

 LOCATION

C/ Isabel Colbrand 6
4ª Planta B
28050 Madrid (Spain)

OPENING HOURS

L - J :  9:00–18:00 hs

V :  9:00–15:00 hs